News

Understanding and addressing the myths and realities of vertigo, a common but often misunderstood symptom with effective ...
A recent study published in the Nature and Science of Sleep found that poor sleep quality significantly increases the ...
While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...
NICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft guidance. Ultomiris is Alexion’s follow-up to ...
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...
Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.
The offspring of women who ate avocado during pregnancy are less likely to have a food allergy at age 12 months vs. those ...
Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...
Prime Minister Alix Didier Fils-Aimé returned to the country. The Head of Government presented the results of his diplomatic ...
The representative added, "Our goal is to offer a complete rehabilitation experience that caters to the diverse needs of our patients. Through specialized services like Vestibular Therapy, we aim to ...
A number of planning application decisions were made by City of Bradford Metropolitan District Council in the week beginning ...
Have you ever stood up too quickly and felt the room spin? Or rolled over in bed and suddenly felt like you were on a merry ...